These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15133623)

  • 1. Optimal HIV treatment by maximising immune response.
    Culshaw RV; Ruan S; Spiteri RJ
    J Math Biol; 2004 May; 48(5):545-62. PubMed ID: 15133623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal control of the chemotherapy of HIV.
    Kirschner D; Lenhart S; Serbin S
    J Math Biol; 1997 Aug; 35(7):775-92. PubMed ID: 9269736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fuzzy modeling and control of HIV infection.
    Zarei H; Kamyad AV; Heydari AA
    Comput Math Methods Med; 2012; 2012():893474. PubMed ID: 22536298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model predictive control based scheduling method for HIV therapy.
    Zurakowski R; Teel AR
    J Theor Biol; 2006 Jan; 238(2):368-82. PubMed ID: 15993900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal control of HIV dynamic using embedding method.
    Zarei H; Kamyad AV; Farahi MH
    Comput Math Methods Med; 2011; 2011():674318. PubMed ID: 21687584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs versus benefits: best possible and best practical treatment regimens for HIV.
    Krakovska O; Wahl LM
    J Math Biol; 2007 Mar; 54(3):385-406. PubMed ID: 17205357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8 T-cell response to antiretroviral therapy.
    Stricker RB; Goldberg B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):176-7. PubMed ID: 9241121
    [No Abstract]   [Full Text] [Related]  

  • 9. [Theoretical evaluation of optimal and suboptimal antiretroviral therapy strategies for HIV infection].
    Toro-Zapata HD; Trujillo-Salazar CA; Prieto-Medellín DA
    Rev Salud Publica (Bogota); 2018; 20(1):117-125. PubMed ID: 30183894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling IL-7 Injections in HIV-Infected Patients.
    Pasin C; Dufour F; Villain L; Zhang H; Thiébaut R
    Bull Math Biol; 2018 Sep; 80(9):2349-2377. PubMed ID: 30073567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects.
    Smith RJ; Wahl LM
    Bull Math Biol; 2005 Jul; 67(4):783-813. PubMed ID: 15893553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulse HIV vaccination: feasibility for virus eradication and optimal vaccination schedule.
    Yang Y; Xiao Y; Wu J
    Bull Math Biol; 2013 May; 75(5):725-51. PubMed ID: 23535904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus.
    Rouzine IM; Sergeev RA; Glushtsov AI
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):666-71. PubMed ID: 16407101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis A vaccination and immunological parameters in HIV-infected patients.
    Kourkounti S; Papaizos V; Leuow K; Kordosis T; Antoniou C
    Viral Immunol; 2013 Oct; 26(5):357-63. PubMed ID: 24044625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M
    HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical Model for an Effective Management of HIV Infection.
    Ogunlaran OM; Oukouomi Noutchie SC
    Biomed Res Int; 2016; 2016():4217548. PubMed ID: 27057541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.
    Al-Harthi L; Voris J; Du W; Wright D; Nowicki M; Frederick T; Landay A; Kovacs A
    J Infect Dis; 2006 May; 193(9):1202-10. PubMed ID: 16586355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of the transition to long-term nonprogressor in tristable HIV dynamics.
    Chang H; Astolfi A
    Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():4940-4. PubMed ID: 19163825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piecewise virus-immune dynamic model with HIV-1 RNA-guided therapy.
    Tang B; Xiao Y; Cheke RA; Wang N
    J Theor Biol; 2015 Jul; 377():36-46. PubMed ID: 25908208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality.
    Stebbing J; Bower M; Mandalia S; Nelson M; Gazzard B
    Clin Exp Immunol; 2006 Aug; 145(2):271-6. PubMed ID: 16879246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.